A newer immunoglobulin intravenous (IGIV) – Gammagard^® liquid 10%: Evaluation of efficacy, safety, tolerability and impact on patient care

Abstract

Background: Even though all immunoglobulin intravenous (IGIV) end products have high IgG concentrations, variations in manufacturing processes lead to unique product characteristics. Objective: Solvent/detergent-treated IGIV (IGIV-S/D) liquid 10% (Gammagard^® or Kiovig^® liquid) is one of the newer products, and this article will discuss and compare its efficacy, safety, tolerability and effect on patient care. Methods: The search terms ‘immunoglobulin,’ ‘IGIV,’ ‘IVIG,’ and ‘liquid’ were entered into PubMed/Medline and Google for the literature search in preparation of this manuscript. Additional references were screened from researched literature. Results/conclusion: Gammagard liquid 10% has shown significant activity in primary immunodeficiency and immune thrombocytopenic purpura. It is a sugar- and sodium-free product with improved safety, tolerability and convenience. Overall, Gammagard liquid is a valuable addition to available therapies that has utility in life-threatening and complicated diseases, and its use will continue to grow.

Keywords::

• autoimmune disorder
• efficacy
• IGIV
• immunodeficiency
• immunoglobulin
• IVIG
• liquid
• safety

Acknowledgments

The author would like to thank Melissa Eder for her assistance in preparation of this manuscript.